title: Gerontopsychological studies using NAI ('Nürnberger Alters-Inventar') on patients with organic psychosyndrome (DSM III, Category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial.
abstract: A double blind clinical trial was performed on 50 persons (25 men, 25 women) over the age 60 (average age: 77 years). They suffered from dementias of medium level (DSM III, Category 1, ICD No. 299), and had been residents in an old age home longer than 3 months at the start of the trial. The patients were treated first for 2 weeks by placebo tablets and their initial performance was recorded during this period by using the Nuremberg Gerontopsychological Inventory (NAI). This was then followed by a treatment for 8 weeks with the nootropic drug, centrophenoxine (CPH), the dose of which was 2 g/day distributed in 2 x 2 tablets of Helfergin500 (Promonta, Hamburg, FRG), or with placebo tablets of identical size, then the NAI test was repeated again. Verum or placebo treatment was selected randomly and the code was revealed only after having elaborated all the results of the trial. During the treatment period four drop-outs occurred for intercurrent diseases. Evaluation was based on a semi-quantitative, intra-individual comparison of the performance before and after treatment. The results obtained suggest that CPH treatment may be useful in dementias of medium level in quite old groups of patients, since 48% of the verum group displayed improvements in the memory functions against 28% of the placebo group. CPH seems to be a useful and harmless drug in the treatment and most probably also in prevention of the dementias.
authors.affiliation: Department of Neurology and Psychiatry, University Medical School, Debrecen, Hungary.
authors.forename: G
authors.initials: G
authors.lastname: Pék
authors.forename: T
authors.initials: T
authors.lastname: Fülöp
authors.forename: I
authors.initials: I
authors.lastname: Zs-Nagy
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D002504:Meclofenoxate / Q000627:therapeutic use*; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000523:psychology; D011581:Psychological Tests; D011897:Random Allocation
chemical_list: D006016:Glycolates; D002504:Meclofenoxate